PTCT - PTC THERAPEUTICS, INC.

QQQ $ 439.55 $ -0.26 (-0.06 %)

DIA $ 390.50 $ 1.74 (0.45 %)

SPY $ 517.10 $ 0.05 (0.01 %)

TLT $ 90.18 $ -0.55 (-0.61 %)

GLD $ 213.58 $ -0.63 (-0.29 %)

Previous Close

$ 31.14

Open

$ 31.36

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 30.71 - $ 31.36

52 Week Range

$ 17.53 - $ 59.84

Volume

623,773

Average Volume

Market Cap

2.38B

Beta (5Y Monthly)

$ 0.88

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	04-25-2024	03-31-2024	10-Q
2	02-29-2024	12-31-2023	10-K
3	10-26-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	04-27-2023	03-31-2023	10-Q
6	02-21-2023	12-31-2022	10-K
7	10-27-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-03-2022	03-31-2022	10-Q
10	02-22-2022	12-31-2021	10-K
11	10-28-2021	09-30-2021	10-Q
12	07-29-2021	06-30-2021	10-Q
13	05-04-2021	03-31-2021	10-Q
14	02-25-2021	12-31-2020	10-K
15	10-29-2020	09-30-2020	10-Q
16	08-05-2020	06-30-2020	10-Q
17	04-30-2020	03-31-2020	10-Q
18	03-02-2020	12-31-2019	10-K
19	10-30-2019	09-30-2019	10-Q
20	08-06-2019	06-30-2019	10-Q
21	05-02-2019	03-31-2019	10-Q
22	03-01-2019	12-31-2018	10-K
23	11-05-2018	09-30-2018	10-Q
24	08-07-2018	06-30-2018	10-Q
25	05-09-2018	03-31-2018	10-Q
26	03-06-2018	12-31-2017	10-K
27	11-02-2017	09-30-2017	10-Q
28	08-09-2017	06-30-2017	10-Q
29	05-08-2017	03-31-2017	10-Q
30	03-16-2017	12-31-2016	10-K
31	11-03-2016	09-30-2016	10-Q
32	08-04-2016	06-30-2016	10-Q
33	05-05-2016	03-31-2016	10-Q
34	02-29-2016	12-31-2015	10-K
35	11-09-2015	09-30-2015	10-Q
36	07-31-2015	06-30-2015	10-Q
37	05-05-2015	03-31-2015	10-Q
38	03-02-2015	12-31-2014	10-K
39	11-06-2014	09-30-2014	10-Q
40	08-07-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Morgan Stanley Upgrades PTC Therapeutics t...
04/29/2024 09:11:35

Morgan Stanley analyst Jeffrey Hung upgrades PTC Therapeutics (NASDAQ:PTCT) from Underweight to Equal-Weight and raises the ...

PTC Therapeutics Reaffirms FY24 Financial ...
04/25/2024 21:18:50

PTC Therapeutics Says On Target To Achieve...
04/25/2024 21:16:49

PTC Therapeutics Q1 2024 GAAP EPS $(1.20) ...
04/25/2024 20:39:10

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(1.20) per share which beat the analyst consensus estimate of $(1....

Cantor Fitzgerald Reiterates Overweight on...
04/12/2024 13:55:08

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $45 price...

PTC Therapeutics Submits Sepiapterin MAA F...
03/28/2024 12:34:14

- First marketing authorization submission for sepiapterin with additional global submissions to follow in 2024 -

RBC Capital Reiterates Sector Perform on P...
03/08/2024 16:35:37

RBC Capital analyst Brian Abrahams reiterates PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and maintains $28 price t...

cooper-companies-reports-upbeat-results-joins-dell-netapp-tidewater-and-other-big-stocks-moving-higher-on-friday

Cooper Companies Reports Upbeat Results, J...
03/01/2024 16:18:21

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

RBC Capital Maintains Sector Perform on PT...
03/01/2024 15:29:46

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price targe...

Cantor Fitzgerald Reiterates Overweight on...
03/01/2024 14:40:07

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $45 price...

TD Cowen Maintains Market Perform on PTC T...
03/01/2024 13:44:26

TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Market Perform and lowers the price target fro...

PTC Therapeutics Sees FY24 Revenue $600M-$...
02/29/2024 21:40:28

Recap: PTC Therapeutics Q4 Earnings
02/29/2024 21:25:15

PTC Therapeutics Q4 2023 Adj EPS $(0.240) ...
02/29/2024 21:24:51

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.240) per share which missed the analyst consensus estimate of $...

Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

Earnings Preview: PTC Therapeutics
02/28/2024 18:01:04

Cantor Fitzgerald Maintains Overweight on ...
01/26/2024 17:42:52

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price tar...

RBC Capital Maintains Sector Perform on PT...
01/26/2024 15:29:06

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price targe...

ptc-therapeutics-to-withdraw-its-conditionally-approved-rare-muscle-disorder-disorder-drug-in-europe

PTC Therapeutics To Withdraw Its Condition...
01/26/2024 14:00:05

CHMP issues negative opinion on PTC Therapeutics' Translarna for Duchenne Muscular Dystrophy. CEO expresses disappointment.

12-health-care-stocks-moving-in-fridays-pre-market-session

12 Health Care Stocks Moving In Friday's P...
01/26/2024 13:05:58